Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Ehlers-Danlos syndromes (EDS) form a heterogeneous group of inherited connective tissue disorders characterized by variable joint hypermobility and cutaneous hyperextensibility. Type X is distinguished by platelet dysfunction associated with a fibronectin abnormality. Type X EDS has been described in only one family so far. Age of onset is about 13-25 years. Transmission is autosomal recessive.
Features include: Joint hypermobility, Striae distensae, Atypical scarring of skin, and Petechiae and 4 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 3 | Atypical scarring of skin, Thin skin, Hyperextensible skin |
Bones and joints |
Biomarker and diagnostic research for Ehlers-Danlos syndrome, fibronectinemic type has been reported in the published literature.
No clinical trials have been registered for Ehlers-Danlos syndrome, fibronectinemic type.
172 publications have been identified in PubMed for Ehlers-Danlos syndrome, fibronectinemic type. Kisho has analyzed 47 by research type. Research spans Review / Meta-Analysis (34%), Basic Science / Preclinical (28%), and Epidemiology / Natural History (21%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 16 | 34% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 6:52 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Common questions about Ehlers-Danlos syndrome, fibronectinemic type
1
Joint hypermobility |
Heart and blood vessels | 1 | Mitral valve prolapse |
Laboratory research |
13 |
28% |
Disease patterns and progression | 10 | 21% |
Testing and diagnosis research | 3 | 6% |
Patient case studies | 3 | 6% |
Clinical study results | 2 | 4% |
Cuenca-Gómez JA (2026). [PMID: 41554340](https://pubmed.ncbi.nlm.nih.gov/41554340/). *Rev Clin Esp (Barc)*. [Review / Meta-Analysis]
van den Bersselaar LM (2026). [PMID: 40104886](https://pubmed.ncbi.nlm.nih.gov/40104886/). *BJOG*. [Epidemiology / Natural History]
Kumskova M (2026). [PMID: 41284637](https://pubmed.ncbi.nlm.nih.gov/41284637/). *Blood*. [Basic Science / Preclinical]
Miolo G (2026). [PMID: 41338889](https://pubmed.ncbi.nlm.nih.gov/41338889/). *J Proteome Res*. [Basic Science / Preclinical]
Wolfe S (2026). [PMID: 29494034](https://pubmed.ncbi.nlm.nih.gov/29494034/). *Unknown Journal*. [Epidemiology / Natural History]
Brown RF (2025). [PMID: 40705318](https://pubmed.ncbi.nlm.nih.gov/40705318/). *JAMA*. [Review / Meta-Analysis]
Bowen CJ (2025). [PMID: 39836470](https://pubmed.ncbi.nlm.nih.gov/39836470/). *JCI Insight*. [Basic Science / Preclinical]
McCarty RM (2025). [PMID: 39923201](https://pubmed.ncbi.nlm.nih.gov/39923201/). *Ann Clin Transl Neurol*. [Basic Science / Preclinical]
Jeunemaitre X (2025). [PMID: 39906986](https://pubmed.ncbi.nlm.nih.gov/39906986/). *Circulation*. [Clinical Trial Publication]
Ritelli M (2025). [PMID: 39225014](https://pubmed.ncbi.nlm.nih.gov/39225014/). *Am J Med Genet A*. [Diagnostic / Biomarker]